Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age
- PMID: 105053
- DOI: 10.1093/infdis/138.6.731
Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age
Abstract
Infants were immunized with group A Neisseria meningitidis polysaccharide vaccine at two, four, and six months of age. Two lots of group A vaccine that differed in molecular weight were used; lot no. 1980A was of significantly larger molecular size than lot no. A-7. No significant adverse reactions occurred. The geometric mean concentration of serum antibody to group A N. meningitidis one month after the third dose of lot no. 1980A was 0.89 microgram/ml, nearly twice the concentration induced by lot no. A-7 (0.48 microgram/ml). When the infants were 12 months of age, concentrations of antibody in both groups had declined to similar levels, which were still greater than the mean concentration of antibody in unimmunized children. By 18 months of age, the antibody levels of immunized and unimmunized infants were the same. The three-dose schedule resulted in significantly lower concentrations of antibody than previously studied schedules of two doses given three to four months apart.
Similar articles
-
Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.Pediatr Infect Dis J. 2001 Feb;20(2):153-9. doi: 10.1097/00006454-200102000-00007. Pediatr Infect Dis J. 2001. PMID: 11224833 Clinical Trial.
-
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.J Infect Dis. 1979 Nov;140(5):690-7. doi: 10.1093/infdis/140.5.690. J Infect Dis. 1979. PMID: 118997
-
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines.Pediatrics. 1977 Nov;60(5):673-80. Pediatrics. 1977. PMID: 411104
-
The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.Contrib Microbiol Immunol. 1989;10:151-65. Contrib Microbiol Immunol. 1989. PMID: 2479499 Review. No abstract available.
-
The immune response to the capsular polysaccharide of Neisseria meningitidis group B.Zentralbl Bakteriol. 1997 Feb;285(3):331-40. doi: 10.1016/s0934-8840(97)80001-1. Zentralbl Bakteriol. 1997. PMID: 9084108 Review. No abstract available.
Cited by
-
Advances in pneumococcal vaccines: advantages for infants and children.Drugs. 2005;65(2):229-55. doi: 10.2165/00003495-200565020-00005. Drugs. 2005. PMID: 15631543 Review.
-
Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.Infect Immun. 2003 Sep;71(9):5115-20. doi: 10.1128/IAI.71.9.5115-5120.2003. Infect Immun. 2003. PMID: 12933854 Free PMC article.
-
Meningococcal vaccines.Paediatr Drugs. 2004;6(4):251-66. doi: 10.2165/00148581-200406040-00004. Paediatr Drugs. 2004. PMID: 15339202 Review.
-
Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens.Infect Immun. 1983 Nov;42(2):471-9. doi: 10.1128/iai.42.2.471-479.1983. Infect Immun. 1983. PMID: 6417015 Free PMC article.
-
The meningococcus and mechanisms of pathogenicity.Microbiol Rev. 1982 Jun;46(2):162-90. doi: 10.1128/mr.46.2.162-190.1982. Microbiol Rev. 1982. PMID: 6126800 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources